Vindesine
Showing 1 - 25 of 93
Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Rituximab
- +4 more
- (no location specified)
Mar 9, 2023
Classical Hodgkin Lymphoma Trial in Guangzhou (Zimberelimab 240mg)
Recruiting
- Classical Hodgkin Lymphoma
- Zimberelimab 240mg
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-Sen University Cancer Ce
Jun 15, 2023
CNS Lymphoma Trial in Aarhus (Immunochemo)
Completed
- Central Nervous System Lymphoma
-
Aarhus, DenmarkElisa Jacobsen Pulczynski
Aug 3, 2022
Burkitt's Lymphoma, Burkitt's Leukemia, Mediastinal Tumors Trial in Frankfurt (Adriamycin, Cyclophosphamide, Cytarabine)
Completed
- Burkitt's Lymphoma
- +4 more
- Adriamycin
- +10 more
-
Frankfurt, GermanyUniversity Hospital, Medical Dept. II
Aug 17, 2022
Adult Acute Lymphocytic Leukemia Trial in Frankfurt (Cyclophosphamide, Dexamethasone, Vincristine)
Completed
- Adult Acute Lymphocytic Leukemia
- Cyclophosphamide
- +20 more
-
Frankfurt, GermanyUniversity of Frankfurt, Medical Dept. II
Aug 17, 2022
Hodgkin Lymphoma, Chemo Effect Trial in Guangzhou (Tislelizumab)
Recruiting
- Hodgkin Lymphoma
- Chemotherapy Effect
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Apr 12, 2021
Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma Trial in Frankfurt (Main) (Rituximab, Nelarabine, PEG-Asparaginase)
Recruiting
- Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
- Rituximab
- +18 more
-
Frankfurt (Main), GermanyUniversity Hospital of Frankfurt (Main)
Jul 1, 2022
Lymphoblastic Lymphoma Trial in Chengdu, Shanghai (Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide,
Active, not recruiting
- Lymphoblastic Lymphoma
- Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine
- +6 more
-
Chengdu, China
- +1 more
Mar 17, 2022
T-cell Lymphoblastic Lymphoma Trial in Shanghai, Chengdu (Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine,
Not yet recruiting
- T-cell Lymphoblastic Lymphoma
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
- Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
-
Shanghai, Shanghai, China
- +1 more
Dec 27, 2022
High-Risk Neuroblastoma Trial in Worldwide (Vincristine, Carboplatin, Etoposide)
Recruiting
- High-Risk Neuroblastoma
- Vincristine
- +13 more
-
Villejuif, Val De Marne, France
- +15 more
Sep 17, 2021
Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL Trial in Spain
Recruiting
- Mature B-Cell Leukemia Burkitt Type
- +2 more
- Rituximab
- +11 more
-
Badalona, Barcelona, Spain
- +28 more
Sep 17, 2021
Diffuse Large B Cell Lymphoma, Follicular Lymphoma Grade 3B Trial in Changchun (R-CDOP)
Recruiting
- Diffuse Large B Cell Lymphoma
- Follicular Lymphoma Grade 3B
- R-CDOP
-
Changchun, Jilin, ChinaThe First Bethune Hospital of Jilin University
Sep 15, 2021
Diffuse Large B Cell Lymphoma Trial in Suzhou (Rituximab, Orelabrutinib, Pomalidomide)
Recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab
- +4 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Apr 10, 2023
Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)
Recruiting
- Newly Diagnosed Peripheral T-cell Lymphoma
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023
The First Affiliated Hospital of Nanchang University Trial in Nanchang, Jinan (Orelabrutinib+R-CHOP)
Recruiting
- The First Affiliated Hospital of Nanchang University
-
Nanchang, Jiangxi, China
- +1 more
Jul 3, 2023
Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib combined with chemo)
Not yet recruiting
- Philadelphia-Positive ALL
- Olverembatinib combined with chemotherapy
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Jul 17, 2022
Diffuse Large B Cell Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Zanubrutinib and RCHOP)
Not yet recruiting
- Diffuse Large B Cell Lymphoma
- Rituximab, Lenalidomide, Zanubrutinib and RCHOP
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Mar 21, 2022
Acute Lymphoblastic Leukemia, Pediatric Trial in Worldwide (Blinatumomab, Bortezomib, Cyclophosphamide)
Recruiting
- Acute Lymphoblastic Leukemia, Pediatric
- Blinatumomab
- +18 more
-
Sydney, Australia
- +114 more
Nov 1, 2022
DLBCL Trial in Suzhou (Orelabrutinib, Rituximab, CHOP-like Regimen)
Recruiting
- Diffuse Large B-Cell Lymphoma
- Orelabrutinib
- +2 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Aug 10, 2022
B Acute Lymphoblastic Leukemia Trial in Suzhou (Blinatumomab)
Recruiting
- B Acute Lymphoblastic Leukemia
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University, Jiangsu Ins
Nov 1, 2022
High Grade B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements,
Recruiting
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- +4 more
- Zanubrutinib+R-CHOP; Zanubrutinib+R-DA-EPOCH; Zanubrutinib+R-HD MTX
- R-CHOP; R-DA-EPOCH; R-HD MTX
-
Jinan, Shandong, ChinaDepartment of Hematology, Shandong Provincial Hospital
Dec 7, 2021
Philadelphia Positive Acute Lymphoblastic Leukemia Trial in Germany (Dasatinib)
Completed
- Philadelphia Positive Acute Lymphoblastic Leukemia
-
Stuttgart, Baden-Württemberg, Germany
- +21 more
Jan 10, 2022
Lymphoblastic Leukemia, Acute, Adult, Ph Negative ALL, Newly Diagnosed Trial in Czechia (Blinatumomab)
Active, not recruiting
- Lymphoblastic Leukemia, Acute, Adult
- +2 more
-
Brno, Czechia
- +4 more
Aug 3, 2022
Diffuse Large B Cell Lymphoma Trial in Wenzhou (Zanubrutinib+Rituximab+Lenalidomide, RCHOP/RCDOP)
Recruiting
- Diffuse Large B Cell Lymphoma
-
Wenzhou, Zhejiang, ChinaFirst Affiliated Hospital of Wenzhou Medical University
Jun 20, 2022